|Bid||0.00 x 1400|
|Ask||0.00 x 2200|
|Day's Range||7.21 - 7.64|
|52 Week Range||5.42 - 20.60|
|Beta (5Y Monthly)||0.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2023 - Feb 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.85|
Subscribe to Yahoo Finance Plus to view Fair Value for IOVA
SAN CARLOS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences: Piper Sandler 34th Annual Healthcare ConferenceFireside Chat: November 30, 2022 at 10:30 a.m. ET / 7:30 a.m. PTNew York, NY JMP Securities Hematology and Oncology SummitFireside Chat: December 7, 2022 at 11:00 a.m. ET / 8:00
Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.
The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy.